Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.
Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
New for the week ending March 15: Study of young black MSM finds no link between PrEP uptake and STI incidence; HIV risk scores and PrEP usage; impact of youth-tailored HIV services; long-acting antiretroviral interest among younger people with HIV.
Cardiorespiratory fitness and inflammation among sedentary people with HIV; helping patients increase physical activity; transwomen and metabolic syndrome; failed treatment of precancerous cervical lesions.
The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
Unmet subsistence needs and clinical outcomes; finding HIV treatment success alongside quality-of-life issues; the potential value of facility-level HIV care continuum data; stimulant use and viral suppression.